Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FGFR-TACC approaches the first turn in the race for targetable GBM mutations.

Neuro-oncology - 1 Apr 2017

Brennan Cameron

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Glioblastoma
Share to Mutation

Source

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Identifiers

PMID: 28388710
DOI: 10.1093/neuonc/nox005
PMCID: PMC5464322

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FGFR-TACC approaches the first turn in the race for targetable GBM mutations.PMID 28388710Read ↗

RET-oncogene-targeting drugs draw notice.Semantic proximity Read ↗

Genetic and epigenetic landscape of IDH-wildtype glioblastomas with FGFR3-TACC3 fusionsSemantic proximity Read ↗

ctDNA guides anti-EGFR rechallenge.Semantic proximity Read ↗

Diffuse Gliomas with FGFR3-TACC3 Fusions: Oncogenic Mechanisms, Hallmarks, and Therapeutic PerspectivesSemantic proximity Read ↗

FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signalingSemantic proximity Read ↗

RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectivesSemantic proximity Read ↗

FGFR a promising druggable target in cancer: Molecular biology and new drugs.Semantic proximity Read ↗

Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies.Semantic proximity Read ↗

Fast-TRKing Drug Development for Rare Molecular Targets.Semantic proximity Read ↗

GBM radiosensitizers: dead in the water…or just the beginning?Semantic proximity Read ↗

[Histology-agnostic tumor treatment - a farewell to tumor entities?]Semantic proximity Read ↗

Target-Driven Tissue-Agnostic Drug Approvals; a New Path of Drug DevelopmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.